CRL cleared on manufacturing, not efficacy — Q4 resubmission with new CMO is the make-or-break event for a well-funded approval story

Achieve Life Sciences is a clinical-stage biotech company developing cytisinicline, a targeted smoking-cessation drug that is not yet approved.

Cytisinicline, a nicotinic receptor partial agonist for smoking cessation, earned a CRL solely on manufacturing deficiencies at its prior supplier, with FDA explicitly clearing the clinical package. A $354 million private placement funds the resubmission, a Phase 3 e-cigarette cessation trial, and commercialization buildup — removing the financing overhang. The single pivot is whether the Adare manufacturing transfer satisfies FDA on resubmission; a second CRL on CMC grounds would structurally undermine the approval path.